September 3, 2024
Alliance A072201 Randomized phase II trial of anti-lag-3 and anti-PD-1 blockade vs. SOC in patients with recurrent glioblastoma
Michael Lim, MD, of Stanford University School of Medicine, leads Alliance A072201 – a phase II trial to compare the safety, side effects and effectiveness of anti-lag-3 (relatlinib) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patien
August 15, 2024
Results from a quality assurance analysis of Alliance A021501, the first randomized trial to evaluate stereotactic body radiation therapy (SBRT) for borderline resectable pancreatic cancer after neoadjuvant chemotherapy, may help inform future clinical trial designs for patients, according to a newly released article in the International Journal of Radiation, Biology, Physics. Read more about
- Application is based on results from the Alliance A021602 (CABINET) pivotal trial, in which cabozantinib provided a statistically significant and clinically meaningful improvement in progression-free survival versus placebo
August 6, 2024
A supplemental New Drug Application (sNDA) for cabozantinib, submitted by Exelixis, Inc., ha
